Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Annual capacity will exceed $1 billion of plasmid DNA, RNA, gene editing enzymes, and other biologics
June 3, 2019
By: Kristin Brooks
Managing Editor, Contract Pharma
Aldevron, a producer of plasmid DNA, proteins, mRNA and antibodies, is planning an expansion at its 14-acre campus headquarters in Fargo, ND, which will begin in August. Upon completion, the annual capacity will exceed $1 billion of plasmid DNA, RNA, gene editing enzymes, and other biologics. The first building will increase Aldevron’s GMP and GMP-Source production capacity up to 10 times its current output. The new 189,000 sq.-ft. building will connect to the existing GMP facility and is expected to be fully operational by 1Q21. In total, three new buildings will be built over the next three to five years to support the rapidly growing field of genetic medicine. Plans include adding 20,000 sq.-ft. of additional Quality Control and product storage space to Aldevron’s current 70,000 sq.-ft. GMP and GMP-Sourcemanufacturing building, which is among the world’s largest plasmid DNA manufacturing facilities. Another building will add 89,000 sq.-ft., for an administration and client visit center, connected to the manufacturing space. The final building will be a 96,000 sq.-ft. research and development, technical operations and training center. Once complete, the total square footage will be nearly 0.5 million square feet and has potential to employ 1,000 people. “This plan is designed to serve the biopharmaceutical industry with the world’s most advanced manufacturing platforms for gene and cell therapy,” said Michael Chambers, chief executive officer of Aldevron. “It is an honor for us to provide plasmids, gene editing enzymes, and other biologics to support clinical and commercial applications that our clients are pioneering.” Chambers added that the new campus will also enable large-scale production of novel products like nanoplasmids and minicircles. “Our industry is growing exponentially. We are building a campus to meet client demand, create a functional and inspiring environment for our staff, and take us to the next level,” said Henry Hebel, chief operating officer for Aldevron. “Our robust expansion plan was designed by listening to and engaging with regulatory agencies, industry professionals and most importantly, our clients. The design decisions promote efficiency and scaling, and the next generation of manufacturing optimization.”
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !